Skip to main content

Zelnorm Side Effects

Generic name: tegaserod

Medically reviewed by Last updated on Apr 6, 2023.

Note: This document contains side effect information about tegaserod. Some dosage forms listed on this page may not apply to the brand name Zelnorm.

Applies to tegaserod: oral tablet.

Serious side effects of Zelnorm

Along with its needed effects, tegaserod (the active ingredient contained in Zelnorm) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking tegaserod:

More common

Less common


Incidence not known

Get emergency help immediately if any of the following symptoms of overdose occur while taking tegaserod:

Symptoms of overdose

Other side effects of Zelnorm

Some side effects of tegaserod may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

Incidence not known

For Healthcare Professionals

Applies to tegaserod: oral tablet.


Cardiovascular side effects have included hypotension, angina pectoris, syncope, arrhythmia, bundle branch block, supraventricular tachycardia, and flushing. A case of myocardial infarction has been reported.[Ref]

Myocardial infarction has been reported in a 64-year-old male after receiving two doses of tegaserod 6 mg.[Ref]

Nervous system

Nervous system side effects have included headache, dizziness, migraine, insomnia, vertigo, and Raynaud's phenomenon.[Ref]


Gastrointestinal side effects have included abdominal pain, diarrhea, nausea, flatulence, abdominal distention and pain, vomiting, dyspepsia, gastritis, gastroesophageal reflux, hemorrhoids, and proctalgia. Irritable colon, fecal incontinence, tenesmus, increased appetite, eructation, appendicitis, bilirubinemia, subileus, sphincter of Oddi spasm, bile duct stone, ischemic colitis, mesenteric ischemia, gangrenous bowel, rectal bleeding, and increases in abdominal surgeries, primarily cholecystectomies, have also been reported; however, causality was not clearly established.[Ref]


Hepatic side effects have included increased SGOT and SGPT. Hepatitis, elevation in ALT, AST, and bilirubin have been reported during postmarketing experience.[Ref]


Metabolic side effects have included increase in appetite, hypokalemia and hypovolemia secondary to diarrhea, and increased creatine phosphokinase.[Ref]


Musculoskeletal side effects have included back pain, arthropathy, and myalgia. Other effects, regardless of causality, have included cramps.[Ref]


Oncologic side effects have included breast carcinoma.[Ref]


Psychiatric side effects have included attempted suicide, impaired concentration, emotional lability, increased appetite, sleep disorder and depression.[Ref]


Respiratory side effects have included asthma.[Ref]


Dermatologic side effects have included pruritus. Alopecia has been reported during postmarketing experience.[Ref]


Endocrine side effects have included increased sweating.[Ref]


Genitourinary side effects have included frequent micturition, polyuria, urinary tract infection, ovarian cyst, miscarriage, dysmenorrhea, and menorrhagia.[Ref]


Renal side effects have included renal pain and albuminuria.[Ref]


Side effects affecting the body as a whole have included accidental trauma (3% vs. 2% for placebo) and leg pain (1% vs. less than 1% for placebo). Other effects, regardless of causality, have included pain and facial edema.[Ref]

Frequently asked questions


1. (2002) "Product Information. Zelnorm (tegaserod)." Novartis Pharmaceuticals

2. Morganroth J, Ruegg PC, Dunger-Baldauf C, Appel-Dingemanse S, Bliesath H, Lefkowitz M (2002) "Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects." Am J Gastroenterol, 97, p. 2321-7

3. Busti AJ, Murillo JR Jr, Cryer B (2004) "Tegaserod-induced myocardial infarction: case report and hypothesis." Pharmacotherapy, 24, p. 526-31

4. Bertoli R, Girardin F, Russmann S, Lauterburg BH (2003) "Raynaud's phenomenon induced by drugs acting on neurotransmission: two cases under reboxetine and one under tegaserod." Eur J Clin Pharmacol, 58, p. 717

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.